• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

I thought Astellas had good culture.

anonymous

Guest
Highly disappointed in the Shit Show this is turning out to be. Seriously ... lets forcast a 9% growth goal on a drug that is in its twilight ...to say the least. You money sucking people. Get a grip. You can't ask the sales force to grow to that point. Good luck with the launch of the new product.. You will be losing people because you are pathetic.
 

<



The increase in goals is a money saving ploy to help the financial landscape. Wait until you see the PIP values. This is not a good optic heading into a major launch......